Second, biologics are really difficult to copy, and thus even after the patents expire, knock-off biologics (biosimilars) are far less a threat than knock-off small molecules (generics).
FORBES: Strategy: Why Big Pharmas Do What They Do -- And How Silicon Valley Might Help Them Think Differently